Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 1, 2013, Pages 95-101

  Lévesque, Éric ^a,b   Bélanger, Anne Sophie ^a   Harvey, Mario ^a   Couture, Félix ^a,b   Jonker, Derek ^c   Innocenti, Federico ^d   Cecchin, Erica ^e   Toffoli, Giuseppe ^e   Guillemette, Chantal ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Université Laval   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d University of North Carolina   (United States)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; PLACEBO;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BLOOD TOXICITY; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A GENE; VOMITING;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENETIC MARKERS; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84875412938     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.202242     Document Type: Article

References (46)

1. Ando M, Ando Y, Sekido Y, Ando M, Shimokata K, and Hasegawa Y (2002) Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients. Jpn J Cancer Res 93:591-597.
2. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921- 6926.
3. Beutler E, Gelbart T, and Demina A (1998) Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
4. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, and Oude Elferink RP, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
5. Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, and Blanchard RL (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/ irinotecan. Clin Cancer Res 11:1226-1236.
6. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, and Toffoli G (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457-2465.
7. Ciotti M, Basu N, Brangi M, and Owens IS (1999) Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38) by the human UDP- glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 260:199-202.
8. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, Thirouard AS, Selves J, Laurent-Puig P, and Ychou M (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13: 3269-3275.
9. de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, van Schaik RH, Planting AS, van der Gaast A, Eskens FA, and Janssen JT, et al. (2006) Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1&z.ast;28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11:944-954.
10. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, and Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814.
11. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
12. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Byström P, Sørbye H, and Wadelius M (2011) Prediction of irinotecan and 5- fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 11:61-71.
13. Hanioka N, Ozawa S, Jinno H, Ando M, Saito Y, and Sawada J (2001) Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl- 10-hydroxycamptothecin. Xenobiotica 31:687-699.
14. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, and McLeod HL (2007) UGT1A1&z.ast;28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99: 1290-1295.
15. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, and Rudin CM, et al. (2004) Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382-1388.
16. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1&z.ast;28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
17. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT- 11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854.
18. Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, and Chowbay B (2007) Role of UGT1A1&z.ast;6, UGT1A1&z.ast;28 and ABCG2 c.421C.A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98: 1461-1467.
19. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN- 38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
20. Köhle C, Möhrle B, Münzel PA, Schwab M, Wernet D, Badary OA, and Bock KW (2003) Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1&z.ast;28) with other polymorphisms of the UDPglucuronosyltransferase- 1 locus (UGT1A6&z.ast;2 and UGT1A7&z.ast;3) in Caucasians and Egyptians. Biochem Pharmacol 65:1521-1527.
21. Kojima A, Shinkai T, and Saijo N (1993) Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes. Jpn J Clin Oncol 23:116-122.
22. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJ, and Guchelaar HJ; Dutch Colorectal Cancer Group study (2008) UGT1A1&z.ast;28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 99:275-282.
23. Lankisch TO, Schulz C, Zwingers T, Erichsen TJ, Manns MP, Heinemann V, and Strassburg CP (2008) Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol Biomarkers Prev 17:695-701.
24. Maitland ML, Grimsley C, Kuttab-Boulos H, Witonsky D, Kasza KE, Yang L, Roe BA, and Di Rienzo A (2006) Comparative genomics analysis of human sequence variation in the UGT1A gene cluster. Pharmacogenomics J 6:52-62.
25. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, and Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:678-682.
26. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R, and Leon A (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106: 1007-1016.
27. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, and Verweij J, et al. (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592.
28. McLeod HL, Parodi L, Sargent DJ, Marsh S, Green E, Abreu P, Cisar LA, and Goldberg RM (2006) UGT1A1&z.ast;28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. abstract3520 J Clin Oncol 24:3520.
29. Ménard V, Girard H, Harvey M, Pérusse L, and Guillemette C (2009) Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat 30:677-687.
30. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T (2008) Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
31. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, and Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168.
32. Peters WH, te Morsche RH, and Roelofs HM (2003) Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J Hepatol 38:3-8.
33. Pillot GA, Read WL, Hennenfent KL, Marsh S, Gao F, Viswanathan A, Cummings K, McLeod HL, and Govindan R (2006) A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol 1:972-978.
34. Rothenberg ML, Kuhn JG, Burris HA, 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, and Rodriguez GI, et al. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204.
35. Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, and Sharma A, et al. (2001) Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12:1631-1641.
36. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, and Wils J, et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412.
37. Rouits E, Boisdron-Celle M, Dumont A, Guérin O, Morel A, and Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151-5159.
38. Ruzzo A, Graziano F, Loupakis F, Santini D, Catalano V, Bisonni R, Ficarelli R, Fontana A, Andreoni F, and Falcone A, et al. (2008) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 8:278-288.
39. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, and Pirotta N, et al.; Irinotecan Study Group (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914.
40. Schulz C, Boeck S, Heinemann V, and Stemmler HJ (2009) UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy? Anticancer Drugs 20:867-879.
41. Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, and Ter Steeg J, et al. (2005) Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. Clin Cancer Res 11:1504-1511.
42. Stephens M and Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
43. Stephens M, Smith NJ, and Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
44. Thomas SS, Li SS, Lampe JW, Potter JD, and Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27: 717.
45. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, Pasetto LM, Pessa S, Errante D, and De Pangher V, et al. (2006) The role of UGT1A1&z.ast;28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061-3068.
46. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, and Rustum YM (2001) Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19: 1501-1518.